Fluofarma High Content Screening technology enables large-scale analysis
of compounds in their real cellular environment. Thus, in contrast to standard
drug discovery methods, Fluofarma's HCS technology is both
powerful and highly predictive.
Our technology enables:
• Functional measuring: Assessment of
molecular events in living cells
• Multiplexing analysis: Measure of
up to 5 parameters simultaneously in single cells
► Fluofarma's proprietary
technology affords a highly predictive method for identifying, selecting,
characterizing and understanding any kinds of compounds and its effects.
Roche adopts Fluofarma’s platform
October 19, 2009 – Fluofarma announced today that it entered into
a multi-year agreement with Roche.
Read
More